《大行報告》大和首予康方生物(09926.HK)「買入」評級 目標價45元
大和發表研究報告,首次給予康方生物(09926.HK)「買入」評級,認為市場低了估康方生物的雙特異性抗體新藥AK104(PD-1/CTLA-4bsAb)及其他候選藥物的潛力。
該行指出,Nivolumab(PD-1 mAb)加上Ipilimumab(CTLA-4 mAb)是一種公認的聯合療法,而從理論上,對比安全性較佳的單克隆抗體,雙特異性抗體應具有相似的功效,認為康方的AK104用於治療惡性胸膜間皮瘤的數據亦反映該藥有潛力。
大和指,康方生物有9種藥物正在臨床試驗中,有3種藥物即將進入臨床試驗,估計總峰值收入為350億元人民幣,認為目前股價尚未完全反映出AK104的領先優勢及其他早期藥物的潛力,予目標價45元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.